SCHEMBL6549409

SCHEMBL6549409

CC(=O)c1ccc(OCCCCCOc2c(Cl)cc(OCC=C(Cl)Cl)cc2Cl)cc1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.54
HTT P42858 2/20 0.47
MAOB P27338 5/20 0.43
MAOA P21397 3/20 0.41
MAPT P10636 3/20 0.41
ALDH1A1 P00352 1/20 0.41
POLB P06746 2/20 0.40
APEX1 P27695 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
HRH3 Q9Y5N1 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
PLA2G4B P0C869 1/20 0.39
LMNA P02545 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6548648 0.99 L3MBTL1 (0.55) GAAL3MBTL1HTTMAOBMAOA
SCHEMBL6547877 0.96 L3MBTL1 (0.51) GAAL3MBTL1HTTMAOBMAOA
SCHEMBL6547959 0.95 HTT (0.49) GAAL3MBTL1HTTMAOBMAOA
SCHEMBL8897462 0.89 TP53 (0.49) L3MBTL1HTTALDH1A1POLBAPEX1
SCHEMBL8022488 0.89 HTT (0.43) GAAL3MBTL1HTTMAPTHRH3
SCHEMBL5690281 0.88 HTT (0.47) GAAL3MBTL1HTTMAOBMAOA
SCHEMBL8894549 0.88 TP53 (0.47) L3MBTL1HTTALDH1A1POLBAPEX1
SCHEMBL8021472 0.87 HTT (0.43) GAAL3MBTL1HTTMAPTHRH3
SCHEMBL6547457 0.86 HTT (0.40) GAAL3MBTL1HTTMAOAMAPT
SCHEMBL6549415 0.86 HTT (0.41) GAAL3MBTL1HTTMAOBMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0975586-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION Sumitomo Chemical Company, Limited (JP) 2000-02-02 EP claimed
WO-1998045254-A2 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1998-10-15 WO claimed
EP-0975586-B1 OXIME COMPOUNDS, THEIR USE, AND INTERMEDIATES FOR THEIR PRODUCTION SUMITOMO CHEMICAL CO (JP) 2004-12-01 EP disclosed
US-6448444-B2 INSECTICIDES, MITICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-09-10 US disclosed
US-6437184-B1 INSECTICIDES, ACARICIDES SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2002-08-20 US disclosed
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production SUMITOMO CHEMICAL COMPANY, LIMITED 2002-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019569-A1 Oxime compounds, their use, and intermediates for their production CBR3, CBR1, NOX3 GAA 3855/4885L3MBTL1 876/4885HTT 4052/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.